MEDICREA® Secures Several New Patents to Protect its Proprietary platform technology UNiD ASI
17 Juin 2019 - 11:50AM
Business Wire
The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED
; OTCQX Best Market –MRNTF), pioneering the transformation of
spinal surgery through Artificial Intelligence, predictive modeling
and patient specific implants with its UNiD® ASI (Adaptive Spine
Intelligence) proprietary software platform, services and
technologies, announced today that the United States Patent Office
has recently issued the Company additional key patents related to
the UNiD ASI proprietary technology platform.
Over the last few years, MEDICREA® has had a leading role in
revolutionizing the personalized spine surgery. Its disruptive
ideas and innovative patient specific technologies have been
instrumental in shaping the future spine industry business model
associating precise analysis of each patient and pre-op planning
expert services to the implants. The Company has been actively
protecting these innovations through an aggressive patent strategy
building a IP portfolio that includes 10 independent families, 5
issued patents and 16 pending applications.
The 3 newly allowed patents (U.S. Patent No 10,318,655;
10,314,657; 10,292,770) are directed to fundamental technologies
and methods embedded in the UNiD ASI platform, a breakthrough in
spine surgery. These additional allowances enable the Company to
further expand its existing patent portfolio as the Company
continues to protect its technology directed to:
- The use of Artificial Intelligence and
Predictive Modeling in spine surgery
- Systems and methods for generating data
to produce patient-specific 2D and 3D rods
- Patient-specific screw planning and
screw kit generation
- Patient-specific cage planning and
production
- Intra operative monitoring device
MEDICREA®’s proprietary UNiD ASI™ technology is a comprehensive
suite of services designed to help surgeons improve their patient’s
outcomes. By leveraging artificial intelligence and the latest
clinical research, the platform enables the surgeon to plan cases
preoperatively. The Artificial Intelligence embedded within the
platform allows a surgeon to visualize the compensatory mechanisms
above and below the instrumented spine that will most likely occur
based on the surgeon’s surgical plan. The surgeons work
hand-in-hand with the UNiD Lab™ biomedical engineers who create
several surgical plans and identify the one that would give the
surgeon’s patient the best outcome.
Through rigorous and centralized processes, MEDICREA® improves
the content of its clinical database with each case, allowing the
proprietary technology to continuously refine the algorithms behind
its predictive model. With over 4000 cases performed through the
UNiD ASI™ technology platform, all including patient-specific
implants, this technology undoubtedly met a market need. The
Company plans to pursue its efforts to spread the technology and
grow its clinical database.
Denys Sournac, Chief Executive Officer of MEDICREA®, concludes,
“MEDICREA® is the pioneer in this new approach of spinal treatment
and was able to file the very first patents covering these
innovations. For this reason, the new patents issued create strong
barriers to entry for competitors. It enables the company to
maintain its competitive advantage and strengthen its leading
position in the market place that is now obviously evolving into
this direction. The Company will pursue its permanent efforts of
enhancing its very unique predictive model with the aim to always
improve patient clinical outcomes”.
About MEDICREA® (www.medicrea.com)
Through the lens of predictive
medicine, MEDICREA® leverages its proprietary software
analysis tools with big data and machine learning technologies
supported by an expansive collection of clinical and scientific
data. The Company is well-placed to streamline the efficiency of
spinal care, reduce procedural complications and limit time spent
in the operating room.
Operating in a $10 billion marketplace, MEDICREA® is a
Small and Medium sized Enterprise (SME) with 200 employees
worldwide, which includes 50 who are based in the U.S. The Company
has an ultra-modern manufacturing facility in Lyon, France housing
the development and production of 3D- printed titanium
patient-specific implants.
For further information, please visit: medicrea.com.
Connect with MEDICREA®
FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE
MEDICREA® is listed on
EURONEXT Growth Paris
ISIN: FR 0004178572
Ticker: ALMED
LEI: 969500BR1CPTYMTJBA37
MEDICREA® is traded on
OTCQX Best Market
Tickers: MRNTY & MRNTF
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190617005353/en/
MEDICREA®Denys SOURNACFounder, Chairman and
CEOdsournac@medicrea.com
Fabrice KILFIGERChief Financial
Officerfkilfiger@medircrea.comTel: +33 (0)4 72 01 87 87